Glucose Fresenius Kabi

Glucose Fresenius Kabi is an intravenous solution for injection that contains glucose monohydrate as the active ingredient. The product is supplied in a sterile aqueous solution, with strength not specified, and is marketed in the European Union. It is classified as an excipient/solvent and used as an energy source in parenteral nutrition and fluid replacement. It requires a prescription and is administered by healthcare professionals under aseptic conditions.

Glucose Fresenius Kabi is indicated for several clinical situations where rapid provision of carbohydrate calories or plasma volume support is needed.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens to supply energy. - Fluid replacement in patients requiring intravenous volume expansion. - Support during perioperative periods to maintain blood glucose levels. - Management of electrolyte-free water deficits in certain clinical settings. - Dilution of other intravenous medications when a compatible carbohydrate source is required. - Provision of caloric support in patients with impaired oral intake or gastrointestinal dysfunction.

When administered intravenously, Glucose Fresenius Kabi may be associated with a range of adverse reactions, most of which are related to the rapid infusion of a carbohydrate solution.

Common: - Transient hyperglycemia, especially in patients with impaired insulin response. - Local irritation or pain at the infusion site. - Nausea or mild gastrointestinal discomfort. - Electrolyte shifts, such as mild hyponatremia. - Mild headache related to rapid osmotic changes. - Temporary increase in serum osmolality.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload and pulmonary edema in patients with compromised cardiac function. - Hypersensitivity reactions, including rash, urticaria, or anaphylaxis. - Metabolic acidosis in the setting of massive glucose infusion.

Prior to using Glucose Fresenius Kabi, clinicians should evaluate patient-specific factors to minimize risks associated with intravenous glucose administration.

- Assess baseline blood glucose and adjust infusion rate in diabetic or insulin‑dependent patients. - Monitor fluid balance and cardiac status to avoid overload, especially in heart failure or renal impairment. - Use caution in patients with known hypersensitivity to glucose solutions or excipients. - Evaluate electrolyte levels, particularly sodium and potassium, before and during therapy. - Avoid rapid bolus administration unless clinically indicated. - Consider compatibility with other IV drugs to prevent precipitation.

Glucose Fresenius Kabi can interact with other intravenous agents or affect the pharmacodynamics of certain medications; awareness of these interactions helps ensure safe co‑administration.

Avoid: - Concurrent infusion with high‑dose insulin without appropriate monitoring. - Mixing with calcium‑containing solutions that may precipitate. - Simultaneous administration with hypertonic saline solutions, which can exacerbate hyperosmolar states.

Use with caution: - Co‑administration with diuretics may increase risk of electrolyte disturbances. - Use alongside beta‑blockers, as they may mask hypoglycemia symptoms. - Concurrent use with other carbohydrate‑containing fluids requires careful calculation of total caloric load. - Administration together with vasopressors may necessitate close hemodynamic monitoring due to potential fluid shifts.